Skip to content
OpenCapital
Get started

Oruka Therapeutics, Inc. ORKA Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies

Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Immunovant, Inc. logo
Immunovant, Inc.IMVT
——

Other financials

Income statement

See full
Revenue-—
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
Oruka Therapeutics, Inc. (ORKA) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $160.99M in Q1 2026.
How has Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value changed year-over-year?
Oruka Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value increased by 3322.3% year-over-year, from $4.7M to $160.99M.